These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36235244)

  • 21. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
    Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
    J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a "Cocktail" of Potential SARS-COV-2 Main Protease Inhibitors through Virtual Screening of Known Chemical Components of Vitex negundo L. ("Lagundi").
    Cayona R; Creencia E
    Med Chem; 2022; 18(3):364-381. PubMed ID: 34148541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.
    Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P
    J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M
    Soulère L; Barbier T; Queneau Y
    Comput Biol Chem; 2021 Jun; 92():107463. PubMed ID: 33677227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
    Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
    Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M
    Mercorelli B; Desantis J; Celegato M; Bazzacco A; Siragusa L; Benedetti P; Eleuteri M; Croci F; Cruciani G; Goracci L; Loregian A
    Antiviral Res; 2022 Aug; 204():105350. PubMed ID: 35688349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal.
    Proia E; Ragno A; Antonini L; Sabatino M; Mladenovič M; Capobianco R; Ragno R
    J Comput Aided Mol Des; 2022 Jul; 36(7):483-505. PubMed ID: 35716228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elucidation of Binding Features and Dissociation Pathways of Inhibitors and Modulators in SARS-CoV-2 Main Protease by Multiple Molecular Dynamics Simulations.
    Xu L; Xie L; Zhang D; Xu X
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorine Atoms on C
    Chaves OA; Rodrigues-Santos CE; Echevarria Á; Sacramento CQ; Fintelman-Rodrigues N; Temerozo JR; Castro-Faria-Neto HC; Souza TMLE
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening.
    Federico LB; Silva GM; da Silva Hage-Melim LI; Gomes SQ; Barcelos MP; Galindo Francischini IA; Tomich de Paula da Silva CH
    Future Med Chem; 2021 Aug; 13(16):1353-1366. PubMed ID: 34169729
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docking Paradigm in Drug Design.
    Sulimov VB; Kutov DC; Taschilova AS; Ilin IS; Tyrtyshnikov EE; Sulimov AV
    Curr Top Med Chem; 2021; 21(6):507-546. PubMed ID: 33292135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulants as Potential SARS-CoV-2 M
    Abo Elmaaty A; Eldehna WM; Khattab M; Kutkat O; Alnajjar R; El-Taweel AN; Al-Rashood ST; Abourehab MAS; Binjubair FA; Saleh MA; Belal A; Al-Karmalawy AA
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.